Associations - Yutuo (zimberelimab)

PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	zimberelimab Sensitive: A1 - Approval zimberelimab Sensitive : A1	zimberelimab Sensitive: A1 - Approval zimberelimab Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	zimberelimab Sensitive: A1 - Approval zimberelimab Sensitive : A1	zimberelimab Sensitive: A1 - Approval zimberelimab Sensitive : A1
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	zimberelimab Sensitive: C1 - Off-label zimberelimab Sensitive : C1	zimberelimab Sensitive: C1 - Off-label zimberelimab Sensitive : C1
PD-L1 expression	Nasopharyngeal Carcinoma	PD-L1 expression	Nasopharyngeal Carcinoma	zimberelimab Sensitive: C1 - Off-label zimberelimab Sensitive : C1	zimberelimab Sensitive: C1 - Off-label zimberelimab Sensitive : C1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	zimberelimab Sensitive: C1 - Off-label zimberelimab Sensitive : C1	zimberelimab Sensitive: C1 - Off-label zimberelimab Sensitive : C1
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	zimberelimab Sensitive: C1 - Off-label zimberelimab Sensitive : C1	zimberelimab Sensitive: C1 - Off-label zimberelimab Sensitive : C1
PD-L1 expression	Endometrial Cancer	PD-L1 expression	Endometrial Cancer	zimberelimab Sensitive: C1 - Off-label zimberelimab Sensitive : C1	zimberelimab Sensitive: C1 - Off-label zimberelimab Sensitive : C1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	zimberelimab + AB928 Sensitive: C2 – Inclusion Criteria zimberelimab + AB928 Sensitive : C2	zimberelimab + AB928 Sensitive: C2 – Inclusion Criteria zimberelimab + AB928 Sensitive : C2
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	zimberelimab + AB154 + AB928 Sensitive: C2 – Inclusion Criteria zimberelimab + AB154 + AB928 Sensitive : C2	zimberelimab + AB154 + AB928 Sensitive: C2 – Inclusion Criteria zimberelimab + AB154 + AB928 Sensitive : C2
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	zimberelimab + AB154 Sensitive: C2 – Inclusion Criteria zimberelimab + AB154 Sensitive : C2	zimberelimab + AB154 Sensitive: C2 – Inclusion Criteria zimberelimab + AB154 Sensitive : C2
PD-L1 overexpression	Non-Hodgkin’s Lymphoma	PD-L1 overexpression	Non-Hodgkin’s Lymphoma	zimberelimab Sensitive: C3 – Early Trials zimberelimab Sensitive : C3	zimberelimab Sensitive: C3 – Early Trials zimberelimab Sensitive : C3
TMB-H	Endometrial Cancer	TMB-H	Endometrial Cancer	zimberelimab Sensitive: C3 – Early Trials zimberelimab Sensitive : C3	zimberelimab Sensitive: C3 – Early Trials zimberelimab Sensitive : C3
TMB-H	Gastric Cancer	TMB-H	Gastric Cancer	zimberelimab Sensitive: C3 – Early Trials zimberelimab Sensitive : C3	zimberelimab Sensitive: C3 – Early Trials zimberelimab Sensitive : C3
PD-L1 overexpression	Esophageal Squamous Cell Carcinoma	PD-L1 overexpression	Esophageal Squamous Cell Carcinoma	zimberelimab Sensitive: C3 – Early Trials zimberelimab Sensitive : C3	zimberelimab Sensitive: C3 – Early Trials zimberelimab Sensitive : C3
PD-L1 overexpression	Nasopharyngeal Carcinoma	PD-L1 overexpression	Nasopharyngeal Carcinoma	zimberelimab Sensitive: C3 – Early Trials zimberelimab Sensitive : C3	zimberelimab Sensitive: C3 – Early Trials zimberelimab Sensitive : C3
TMB-H	Esophageal Cancer	TMB-H	Esophageal Cancer	zimberelimab Sensitive: C3 – Early Trials zimberelimab Sensitive : C3	zimberelimab Sensitive: C3 – Early Trials zimberelimab Sensitive : C3
PD-L1 overexpression	Esophageal Adenocarcinoma	PD-L1 overexpression	Esophageal Adenocarcinoma	zimberelimab + AB154 Sensitive: C3 – Early Trials zimberelimab + AB154 Sensitive : C3	zimberelimab + AB154 Sensitive: C3 – Early Trials zimberelimab + AB154 Sensitive : C3
PD-L1 overexpression	Gastric Cancer	PD-L1 overexpression	Gastric Cancer	zimberelimab + AB154 Sensitive: C3 – Early Trials zimberelimab + AB154 Sensitive : C3	zimberelimab + AB154 Sensitive: C3 – Early Trials zimberelimab + AB154 Sensitive : C3
PD-L1 overexpression	Gastroesophageal Junction Adenocarcinoma	PD-L1 overexpression	Gastroesophageal Junction Adenocarcinoma	zimberelimab + AB154 Sensitive: C3 – Early Trials zimberelimab + AB154 Sensitive : C3	zimberelimab + AB154 Sensitive: C3 – Early Trials zimberelimab + AB154 Sensitive : C3
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	disitamab vedotin + zimberelimab Sensitive: C4 – Case Studies disitamab vedotin + zimberelimab Sensitive : C4	disitamab vedotin + zimberelimab Sensitive: C4 – Case Studies disitamab vedotin + zimberelimab Sensitive : C4

Yutuo (zimberelimab)

Associations
(20)

Associations
(20)

Yutuo (zimberelimab)

Associations(20)

Associations(20)

Associations
(20)

Associations
(20)